Vertex reported second-quarter revenue of $3.3 billion, a 12% increase year over year. Trikafta continued to anchor the cystic fibrosis franchise, comprising 75% of sales, while next-generation Alyftrek rose to 17% of sales. Vertex raised its 2026 revenue outlook by 96 basis points at the midpoint.
The firm's CF therapies are poised to dominate the lucrative market for the foreseeable future, based on the disease-modifying potential of the drugs, chronic use by patients, and limited competition.
Vertex is highly dependent on the success of its cystic fibrosis franchise, and it could fail to diversify if its other pipeline candidates are not successful.
|
Metric
|
VRTX
|
ALNY
|
GMAB
|
|---|---|---|---|
Price/Earnings (Normalized) | 26.58 | 28.55 | 19.03 |
Price/Book Value | 6.33 | 22.58 | 3.19 |
Price/Sales | 10.30 | 6.60 | 4.78 |
Price/Cash Flow | 26.12 | 21.29 | 19.42 |
|
Metric
|
VRTX
|
ALNY
|
GMAB
|
|---|---|---|---|
Quick Ratio | 2.54 | 2.79 | 2.44 |
Current Ratio | 3.19 | 3.05 | 2.46 |
Interest Coverage | — | 3.12 | 3.88 |
|
Metric
|
VRTX
|
ALNY
|
GMAB
|
|---|---|---|---|
Return on Assets (Normalized) | 18.99% | 22.09% | 11.74% |
Return on Equity (Normalized) | 26.29% | 149.53% | 21.07% |
Return on Invested Capital (Normalized) | 21.93% | 63.06% | 14.75% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G!G%z$n | LOCK|S<L%x | $83B | |||
| argenx SE ADR
ARGX
| LOCK|L&^!Dr | LOCK|?nr | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|ZNzj>WZZ | LOCK|C??v | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&@g?%yd | LOCK|d&S | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&j#@Xv< | LOCK|C><Z | $31B | |||
| Moderna Inc
MRNA
| LOCK|nZ%@<^$ | LOCK|qqm | $25B | |||
| Incyte Corp
INCY
| LOCK|b^K?n# | LOCK|l$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|^^#R^X | LOCK|@z@ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$>Jmx?m | LOCK|$T | $16B |
United States